Skip to main content

Ankylosing Spondylitis Women Show Less Durable Responses to TNF Inhibitors

A study from the Netherlands has shown that the long-term drug survival of TNF inhibitors differ between men and women, with women having a lower long-term retention rate compared to men.  (Citation source: http://bit.ly/2KZQ0DJ)

A single-center, retrospective study of 122 anklylosing spondylitis (AS) patients, analyzed the outcomes of those receiving either  etanercept, adalimumab, or infliximab between 2004 and 2014.

Nearly 40% were women and most AS patients received adalimumab (59.7%), compared to etanercept (28.9%) or infliximab (11.3%).

This 10-year analysis (mean follow-up duration was 5.1 years) showed several interesting results:

  • the best TNFi survival rate with etanercept (85.3% after 3.7 years), followed by adalimumab and infliximab.
  • 17.2% eventually stopped TNFi without starting a new therapy,
  • 26.2% stopped their TNFi and then switched to another anti-TNF agent.
  • TNFi discontinuation were due to inefficacy (52.4%), vollowed by adverse events, especially infections.
  • Women had significantly lower treatment survival than men (women 33.4 mos versus men 44.9 mos (P = .031)
  • Women switched to another drugy more frequently than men (26.9% vs 16.3%)
  • Women were more likely to completely stop anti-TNF therapy (vs. men) (20.8% vs 14.9%, not significant).

 Factors that drive these differences will require further study. 

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject